Spectral AI, Inc.
2.1800-0.02 (-0.91%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · MDAI · USD
Key Stats
Market Cap
66.90MP/E (TTM)
-Basic EPS (TTM)
-0.70Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Spectral AI's Q2 FY2025 revenue dipped 32.3% y/y to $5.1M from BARDA contracts, yet gross margin edged up to 45.2% on efficient labor mix, while operating loss narrowed to $2.1M from $2.4M. Net loss widened to $8.0M, driven by a $5.4M fair-value hit on warrant liabilities after repricing. Cash climbed to $10.5M, bolstered by $8.5M Avenue debt draw (prime +5.25%, due 2028) and $2.7M equity raise; free cash flow not disclosed in the 10-Q. FDA De Novo filing wrapped on June 30. Regulatory hurdles could delay commercialization.
8-K
Q2 revenue dips; FDA milestone hit
Spectral AI reported Q2 2025 research and development revenue of $5.1 million, down 32.0% from $7.5 million in Q2 2024 due to completed BARDA contract trials, yet gross margin held at 45.2%. The company completed its FDA De Novo submission for the DeepView System in June 2025, a key step toward U.S. market approval for burn wound diagnostics. Cash strengthened to $10.5 million, supported by $8.5 million debt drawdown and $2.7 million equity raise; FY 2025 revenue guidance remains $21.5 million. Net loss widened to $7.9 million from $2.9 million, driven by a $5.4 million warrant liability increase.
8-K
FDA De Novo submission
Spectral AI submitted its De Novo request to the FDA for the DeepView System on June 30, 2025, targeting burn care in centers and emergency departments. This non-invasive tool uses multispectral imaging and AI, trained on over 340 billion data points, to predict healing potential same-day or up to seven days post-injury. Submission marks a key milestone. Yet regulatory approval remains uncertain amid forward-looking risks.
8-K
Auditor switch amid control issues
Spectral AI dismissed KPMG as its independent auditor on May 29, 2025, effective immediately, after the Audit Committee cited ongoing material weaknesses in internal controls from prior years. The board then engaged Forvis Mazars Group as the new firm for the fiscal year ending December 31, 2025, with no prior consultations or disagreements noted. This switch underscores persistent financial reporting challenges. No clean break yet.
8-K
Micek named permanent COO
Spectral AI promoted Stanley Micek to permanent Chief Operating Officer on May 30, 2025, after his year-long interim stint overseeing data science, software, hardware, imaging, and systems teams for the FDA submission. With over 25 years in healthcare and wound expertise from roles at MiMedx and Ohio State, he brings proven leadership to drive operations. His $360,000 base salary underscores commitment to strategic execution amid forward-looking FDA goals. Risks include uncertainties in regulatory approvals.
AIMD
Ainos, Inc.
3.64+0.06
HSCS
HeartSciences Inc.
2.97-0.19
HWAIF
HealWELL AI Inc.
1.04-0.02
INBS
Intelligent Bio Solutions Inc.
0.95-0.06
IRME
IR-Med Inc.
0.03+0.00
MSAI
MultiSensor AI Holdings, Inc.
1.01+0.16
NNOX
NANO-X IMAGING LTD
3.74-0.15
OHCFF
LIGHT AI INC.
0.12-0.00
PMEDF
PREDICTMEDIX AI INC.
0.03-0.00
RBOT
Vicarious Surgical Inc.
5.45-0.30